<DOC>
	<DOCNO>NCT01370330</DOCNO>
	<brief_summary>This compassionate use protocol allow patient advanced neuroblastoma palliative access 131I-metaiodobenzylguanidine ( 131I-MIBG ) .</brief_summary>
	<brief_title>131I-Labeled MIBG Refractory Neuroblastoma : A Compassionate Use Protocol</brief_title>
	<detailed_description>Neuroblastoma remain fatal disease large percentage patient , especially high-risk disease feature become resistant conventional therapy . 131I-metaiodobenzylguanidine ( 131I-MIBG ) norepinephrine analog concentrate adrenergic tissue therefore hold promise cell-specific treatment neuroblastoma . 131I-MIBG active relapse refractory neuroblastoma associate hematopoietic toxicity abrogate autologous stem cell rescue . 131I-MIBG give dos 10-18 mCi/kg stem cell rescue , necessary , safe effective palliative therapy refractory relapse neuroblastoma patient .</detailed_description>
	<mesh_term>Neuroblastoma</mesh_term>
	<mesh_term>3-Iodobenzylguanidine</mesh_term>
	<criteria>Diagnosis : Refractory relapse neuroblastoma original diagnosis base tumor histopathology elevate urine catecholamine typical tumor cell bone marrow . Age &gt; 1 year able cooperate radiation safety restriction therapy period . Life Expectancy : great 6 week . Lanksy Karnofsky Performance Status : 60 % high . Disease status : Failure respond standard therapy ( usually combination chemotherapy without radiation surgery ) development progressive disease time ( new lesion increase size &gt; 25 % preexist lesion ) . Disease evaluable MIBG scan must present within 6 week study entry subsequent intervening therapy . Stem cell : Patients must autologous hematopoietic stem cell product available reinfusion MIBG treatment dose &gt; 12 mCi/kg need . The minimum quantity purge unpurged peripheral blood stem cell 1.0 x 106 CD34+ cells/kg ( optimum &gt; 2 x 106 CD34+ cells/kg ) . The minimum dose bone marrow 1.0 x 108 mononuclear cells/kg ( optimum &gt; 2.0 x 108 mononuclear cells/kg ) . If stem cell available , dose 131IMIBG &lt; 12 mCi/kg . Prior Therapy : Patients may enter study without reinduction therapy recurrent tumor . Patients must fully recover toxic effect prior therapy . At least 2 week elapse since antitumor therapy patient must meet hematologic criterion . Three month elapse case complete radiation follow field : craniospinal , total abdominal , whole lung , total body irradiation ) . Cytokine therapy ( eg GCSF , GMCSF , IL6 , erythropoietin ) must discontinue minimum 24 hour prior MIBG therapy . Prior 131IMIBG therapy allow &gt; 6 month previous patient adequate hematopoietic stem cell available . Organ Function Liver function : bilirubin &lt; 2x normal AST/ALT &lt; 10x normal . Kidney function : Creatinine le equal 2 Hematopoietic Criteria Patients must adequate hematopoietic function ( without transfusion ) : ANC &gt; .750 x 10E9/L ; Platelets &gt; 50 x 10E9/L stem cell available ; stem cell available , patient independent platelet transfusion platelet count least 20 x 10E9/L . Hemoglobin &gt; 10g/dl time treatment ( transfusion allow ) . Patients granulocytopenia and/or thrombocytopenia due tumor metastatic bone marrow may eligible discussion Dr. Matthay designee . Normal lung function manifest dyspnea rest exercise intolerance , oxygen requirement . No clinically significant cardiac dysfunction Signed informed consent : The patient and/or patient 's legally authorized guardian must acknowledge write consent become study subject obtain , accordance institutional policy approve U.S. Department Health Human Services . Patients disease major organ system would compromise ability withstand therapy . Any significant organ impairment discuss Study Chair Vice Chair prior patient entry . Because teratogenic potential study medication , patient pregnant lactate allow . Patients childbearing potential must practice effective method birth control participate study , avoid possible pregnancy . Patients hemodialysis . Patients active infection meet grade 34 toxicity criterion .</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>Neuroblastoma</keyword>
	<keyword>MIBG</keyword>
	<keyword>131I-MIBG</keyword>
	<keyword>Resistant</keyword>
	<keyword>Relapsed</keyword>
	<keyword>Treatment</keyword>
	<keyword>UCSF</keyword>
	<keyword>Pediatric</keyword>
	<keyword>Oncology</keyword>
</DOC>